Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

Comparative efficacy of second-line treatments for advanced hepatocellular carcinoma: A network meta-analysis.

(2020) Neehar Parikh et al.   JOURNAL OF CLINICAL ONCOLOGY

Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer

(2019) Simon Chowdhury et al.   ADVANCES IN THERAPY

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis

(2018) Elvira Schmidt et al.   Targeted Oncology

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

(2018) Gabriel Tremblay et al.   Cancer Management and Research

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Second-line Treatments of Advanced Hepatocellular Carcinoma

(2018) Ziad Bakouny et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA

(2018) N. Roskell et al.   VALUE IN HEALTH

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC): Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib

(2017) M Venkatachalam et al.   VALUE IN HEALTH

TAM receptor tyrosine kinase function and the immunopathology of liver disease

(2016) S. K. Mukherjee et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Matching Adjusted Indirect Comparisons To Assess Comparative Effectiveness Of Therapies: Usage In Scientific Literature And Health Technology Appraisals

(2016) H Thom et al.   VALUE IN HEALTH

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

(2015) Andrew X Zhu et al.   LANCET ONCOLOGY

Evaluating the Quality of Evidence from a Network Meta-Analysis

(2014) Georgia Salanti et al.   PLoS One

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE